Accessibility Menu
Universal Biosensors logo

Universal Biosensors(ASX) UBI

This security has been delisted. This page is retained for historical reference.

Universal Biosensors last closing stock price
MetricPriceDate
Last closeAUD 0.012025-08-19
Universal Biosensors stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-41.67%AUD 0.022025-08-12
1 month-41.67%AUD 0.022025-07-18
3 month-70.83%AUD 0.052025-05-21
Year to date-86.67%AUD 0.112024-12-31
1 year-90%AUD 0.142024-08-19
3 year-95.17%AUD 0.292022-08-19
5 year-95.48%AUD 0.312020-08-20
Since inception-98.44%AUD 0.902006-12-13

UBI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

UBI Financials

Key Financial Metrics (TTM)

Gross Margin

-13.15%

Operating Margin

-404.29%

Net Income Margin

-378.10%

Return on Equity

-101.41%

Return on Capital

-79.36%

Return on Assets

-69.94%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

A$1.40M

Operating Income

-A$20.00M

EBITDA

-A$16.78M

Operating Cash Flow

-A$12.97M

Capital Expenditure

-A$340.15K

Free Cash Flow

-A$13.31M

Cash & ST Invst.

A$2.20M

Total Debt

A$3.05M

Universal Biosensors Performance Analysis

Universal Biosensors annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31AUD 5,777,751N/A
20222022-12-31AUD 4,524,962-21.7%
20232023-12-31AUD 6,632,83846.6%
20242024-12-31AUD 6,282,738-5.3%
Universal Biosensors sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-3014.8%
Q42024-12-31-29.2%
Q12025-03-3117.7%
Q22025-06-30-22.2%
Universal Biosensors annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31AUD -0.06N/A
20222022-12-31AUD -0.14128.6%
20232023-12-31AUD -0.03-76.5%
20242024-12-31AUD -0.0566.2%
Universal Biosensors sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-3018.6%
Q42024-12-31-6.1%
Q12025-03-31-6.6%
Q22025-06-30-72.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

A$1.21M

-25.6%

Gross Profit

-A$1.21M

-230.4%

Gross Margin

-99.83%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

76

N/A

Net Income

-A$6.61M

-74.2%

EBITDA

-A$6.44M

-51.2%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

A$2.20M

-86.8%

Total Debt

A$3.05M

-23.0%

Accounts Receivable

A$1.41M

-31.7%

Inventory

A$3.28M

-39.9%

Long Term Debt

A$2.22M

-20.2%

Short Term Debt

A$826.41K

-29.4%

Return on Assets

-69.94%

N/A

Return on Invested Capital

-1.04%

N/A

Free Cash Flow

-A$2.14M

-501.0%

Operating Cash Flow

-A$2.13M

-475.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VTI.AXVisioneering Technologies, Inc.
A$0.07+0.00%
AMT.AXAllegra Medical Technologies Limited
A$0.03+0.00%
UCM.AXUscom Limited
A$0.01+9.09%
RGS.AXRegeneus Ltd
A$0.01+33.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.90+0.09%
NOKNokia
$10.74+0.07%
BNCCea Industries
$5.11+0.46%
NVDANvidia
$226.38-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.